Business UpdateApr 13, 2026, 07:31 AM
ASP Isotopes Targets $300M+ EBITDA by 2031; First Shipments in 2026
AI Summary
ASP Isotopes Inc. provided a business update, projecting over $300 million in EBITDA by 2031 and expecting first commercial shipments across multiple isotopes in 2026. The company anticipates achieving Helium Phase 1 nameplate capacity in Q3 2026 and reported $333 million in cash and equivalents as of December 31, 2025. Operational progress includes growing radiopharmaceutical revenue and the acquisition of two U.S. radiopharmacies.
Key Highlights
- Targets over $300 million EBITDA by 2031.
- Expects first commercial shipments of Silicon-28, Carbon-14, and Ytterbium-176 in 2026.
- Anticipates Helium Phase 1 nameplate capacity in Q3 2026.
- Held $333 million in cash and equivalents as of December 31, 2025.
- Acquired two radiopharmacies in the United States in October 2025.